红太阳：公司“双万吨级”生物酶及延伸物项目主要应用于终端产品生物制造过程的应用中

Core Viewpoint - The company has faced challenges in achieving expected performance from its "dual ten-thousand-ton" bioenzyme and derivative industry chain project, which has been in operation for over a year [1] Group 1: Project Performance - The "dual ten-thousand-ton" bioenzyme and derivative project is primarily used in the bio-manufacturing process of end products [1] - The company attributes the underperformance to adverse factors such as the release of end product capacity and low-price competition [1] Group 2: Strategic Responses - In response to market challenges, the company is actively optimizing biotechnology, deepening strategic customer collaborations, and innovating marketing models [1] - The company emphasizes that specific operational data should be referenced from its regular reports [1]